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Abstract. 
 
The molecular mechanisms behind pheno-
typic modulation of smooth muscle cells (SMCs) re-
main unclear. In our recent paper, we reported the
establishment of novel culture system of gizzard
SMCs (Hayashi, K., H. Saga, Y. Chimori, K. Kimura,
 
Y. Yamanaka, and K. Sobue. 1998. 
 
J
 
.
 
 Biol
 
.
 
 Chem
 
. 273:
28860–28867), in which insulin-like growth factor-I 
(IGF-I) was the most potent for maintaining the differ-
entiated SMC phenotype, and IGF-I triggered the 
phosphoinositide 3-kinase (PI3-K) and protein kinase 
B (PKB(Akt)) pathway. Here, we investigated the sig-
naling pathways involved in de-differentiation of giz-
zard SMCs induced by PDGF-BB, bFGF, and EGF. In 
contrast to the IGF-I–triggered pathway, PDGF-BB, 
bFGF, and EGF coordinately activated ERK and 
p38MAPK pathways. Further, the forced expression of 
active forms of MEK1 and MKK6, which are the up-
stream kinases of ERK and p38MAPK, respectively,
induced de-differentiation even when SMCs were
stimulated with IGF-I. Among three growth factors, 
 
PDGF-BB only triggered the PI3-K/PKB(Akt) path-
way in addition to the ERK and p38MAPK pathways. 
When the ERK and p38MAPK pathways were simulta-
neously blocked by their speciﬁc inhibitors or an active 
form of either PI3-K or PKB(Akt) was transfected, 
PDGF-BB in turn initiated to maintain the differenti-
ated SMC phenotype. We applied these ﬁndings to
vascular SMCs, and demonstrated the possibility that 
the same signaling pathways might be involved in
regulating the vascular SMC phenotype. These results 
suggest that changes in the balance between the
PI3-K/PKB(Akt) pathway and the ERK and 
p38MAPK pathways would determine phenotypes of 
visceral and vascular SMCs. We further reported that 
SMCs cotransfected with active forms of MEK1 and 
MKK6 secreted a nondialyzable, heat-labile protein 
factor(s) which induced de-differentiation of surround-
ing normal SMCs.
Key words: smooth muscle cells • phosphoinositide
3-kinase • mitogen-activated protein kinases • ERK • 
p38MAPK
 
P
 
HENOTYPIC
 
 modulation of smooth muscle cells
 
(SMCs)
 
1
 
 is critical in the onset of serious diseases
such as atherosclerosis, hypertension, and leiomyo-
genic tumorigenicity. In the progression of these diseases,
SMCs change from a differentiated state to a de-differenti-
ated one (reviewed by Ross, 1993). Differentiated SMCs
show a spindle-like shape and organize their unique intra-
cellular structures including well-developed dense mem-
branes, dense bodies, and myofibrils. They also display
ligand-induced contraction. In contrast, de-differentiated
SMCs lose these characteristic properties. In addition to
these morphological and functional alterations, the ex-
pression levels and/or the isoforms of several proteins
change in the two phenotypes. Therefore, these proteins
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1. 
 
Abbreviations used in this paper:
 
 bFGF, basic fibroblast growth factor;
CM, conditioned medium; CAT, chloramphenicol acetyltransferase;
ERK, extracellular signal-regulated kinase; IGF-I, insulin-like growth fac-
 
tor-I; JNK, c-Jun NH
 
2
 
-terminal protein kinase; MAPKs, mitogen-acti-
vated protein kinases; MBP, myelin basic protein; MT, c-Myc-tag; p70
 
S6K
 
,
p70 ribosomal S6 kinase; PI, phosphatidylinositol; PI3-K, phosphatidyl-
inositol 3-kinase; PKB, protein kinase B; PS, phosphatidylserine; RSV,
Rous sarcoma virus; SMC, smooth muscle cell; X-gal, 5-bromo-4-chloro-
 
3-indolyl-
 
b
 
-
 
D
 
-galactoside. 
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are used as SMC-specific molecular markers (Owens, 1995;
Sobue et al., 1998). For example, the expressions of caldes-
mon (Yano et al., 1995; Kashiwada et al., 1997), calponin
(Gimona et al., 1992; Shanahan et al., 1993), SM22
 
a
 
 
 
(
 
Gi-
mona et al., 1992; Shanahan et al., 1993
 
)
 
, 
 
b
 
-tropomyosin
(Kashiwada et al., 1997), and 
 
a
 
1 integrin (Glukhova et al.,
1993; Obata et al., 1997) at the mRNA and protein levels
are upregulated in differentiated SMCs, but downregu-
lated in de-differentiated SMCs. Isoform changes of
caldesmon (Ueki et al., 1987), 
 
a
 
-tropomyosin (Kashiwada
et al., 1997), vinculin/
 
meta
 
vinculin (Gimona
 
 
 
et al., 1987),
and smooth muscle myosin heavy chain (Nagai et al., 1989;
Kuro-o et al., 1989) are also controlled by SMC pheno-
type-dependent alternative splicings. Recently, the tran-
scription machineries of caldesmon (Yano et al., 1995),
smooth muscle myosin heavy chain (Katoh et al., 1994;
Madsen et al., 1997), SM22
 
a
 
 (Solway et al., 1995; Kim et
al., 1997) and 
 
a
 
1 integrin (Obata et al., 1997) have been
partially characterized. However, the molecular mecha-
nisms behind phenotypic modulation of SMCs remain un-
clear. The slow progress in this area may be due to the
plasticity of SMCs. Under conventional culture conditions,
SMCs in primary culture display a rapid change in their
phenotype (reviewed by Chamley-Campbell et al., 1979).
And, SMC-derived clonal cell lines that maintain a fully
differentiated phenotype have not yet been established.
We have recently established a novel culture system for
gizzard SMCs in which they maintain a differentiated phe-
notype for a long time. Extracellular matrices partially af-
fect the SMC phenotype. Of these, laminin is the most
potent for delaying the progression of SMC de-differentia-
tion, but can not maintain a differentiated phenotype for a
long culture period, suggesting a requirement for addi-
tional factor(s). Among several growth factors and cyto-
kines examined, insulin-like growth factor-I (IGF-I) is the
most potent for maintaining the differentiated SMC. In
the IGF-I–stimulated culture system, phosphoinositide
3-kinase (PI3-K) and its downstream target, protein ki-
nase B (PKB(Akt)), but not mitogen-activated protein ki-
nases (MAPKs), mediate the critical signaling pathways
(Hayashi et al., 1998).
MAPKs have been implicated in the signaling cas-
cades involved in the proliferation and hypertrophy of
SMCs (reviewed by Force and Bonventre, 1998). These in-
clude extracellular signal-regulated kinase (ERK) and the
stress-activated MAPKs, c-Jun NH
 
2
 
-terminal protein ki-
nase (JNK) and p38MAPK. ERK is activated in response
to growth factors, cytokines, and cellular stresses (Ray and
Rturgill, 1988; Denharrdt, 1996), and is involved in a vari-
ety of biological processes (Force and Bonventre, 1998).
Treatment with growth factors such as PDGF, EGF, and
basic fibroblast growth factor (bFGF), which induce the
proliferation or migration of cultured SMCs, activates
ERK. JNK and p38MAPK are also activated by cellular
stresses including inflammatory cytokines, heat shock, os-
molar stress, ultraviolet irradiation, and inhibition of pro-
tein synthesis (Derijard et al., 1994; Kyrian and Avruch,
1996). The ERK and JNK activities are increased in aortic,
carotid, and femoral arteries by hypertensive agents, an-
giotensin II and phenylephrine (Xu et al., 1996). In cul-
tured airway SMCs, endothelin activates both the ERK
and JNK signaling pathways, resulting in cell proliferation
 
(Shapiro et al., 1996). ERK (Pyles et al., 1997), ERK/JNK
(Hu et al., 1997), or p38MAPK (Larrivee et al., 1998) are
enhanced in rat carotid arteries after balloon injury.
p38MAPK is also elicited in airway SMCs by PDGF stim-
ulation (Pyne and Pyne, 1997). These findings suggest that
some smooth muscle disorders are closely associated with
the activation of MAPKs. However, the direct involve-
ment of MAPK pathways in regulating the SMC pheno-
type has not yet been demonstrated.
We investigated the signaling pathways involved in
SMC de-differentiation induced by PDGF-BB, bFGF and
EGF, and compared them with the IGF-I–triggered signal-
ing pathway in maintaining a differentiated phenotype of
gizzard SMC in culture. Here, we demonstrated the first
direct evidence for a mechanism by which the distinctly
different signaling pathways regulate the SMC phenotype.
Both the ERK and p38MAPK pathways triggered by
PDGF-BB, bFGF, and EGF were found to play an essen-
tial role in inducing SMC de-differentiation, whereas the
PI3-K/PKB(Akt) pathway was critical in maintaining a
differentiated state. Interestingly, PDGF-BB only trig-
gered both types of signaling pathways. When the ERK
and p38MAPK pathways were blocked by their specific in-
hibitors, PDGF-BB in turn initiated to maintain a differ-
entiated phenotype of gizzard SMCs. The same signaling
pathways involving in the phenotypic determination were
observed in vascular SMCs. Thus, changes in the balance
between the strengths of the PI3-K/PKB(Akt) pathway
and the ERK and p38MAPK pathways would determine
phenotypes of visceral and vascular SMCs. We further
demonstrated a de-differentiation–inducing factor(s) se-
creted from SMCs in which both the MAPK pathways
were activated by cotransfection with active forms of
MEK1 and MKK6.
 
Materials and Methods
 
Antibodies
 
Anti–PI3-K p85 subunit antiserum was purchased from Upstate Biotech-
nology. Polyclonal antibodies against PKB(Akt), ERK, JNK, p38MAPK,
MEK1, and MKK6 were obtained from Santa Cruz Biotechnology. Mono-
clonal antibodies against c-Myc and Flag were purchased from Santa Cruz
Biotechnology and Sigma Chemical Co., respectively.
 
Plasmids
 
Construction of the caldesmon promoter plasmid, GP3CAT, was de-
scribed previously (Yano et al., 1995). The expression vector containing
the constitutively active form of the c-Myc–tagged PI3-K p110
 
a
 
 subunit
(pCMV5p110
 
a
 
act) was kindly provided by Drs. H. Kurosu and T. Katada
(Department of Physiological Chemistry, Graduate School of Pharmaceu-
tical Sciences, University of Tokyo). This cDNA was constructed by Hu et al.
(1995) and was inserted downstream of the cytomegalovirus promoter,
pCMV5. Expression vectors of constitutively active and dominant-nega-
tive forms of MEK1 and MKK6, and Flag-tagged ERK2 and Flag-tagged
p38MAPK were kindly provided by Dr. K. Sugiyama (Boehringer Ingel-
heim), Drs. M. Hibi and T. Hirano (Osaka University, Medical School),
and Dr. E. Nishida (Graduate School of Science, Kyoto University). Mu-
tant cDNAs of MEK1 and MKK6 were constructed as described else-
where (Mansour et al., 1994; Raingeaud et al., 1996), and were inserted
downstream of the cytomegalovirus promoter of pCS2
 
1
 
 or the SR
 
a
 
 pro-
moter of pcDLSR
 
a
 
296. In this study, we used expression vectors con-
structed in pCS2
 
1
 
 for active and dominant-negative forms of MEK1
(pCS2
 
1
 
MEK1act and pCS2
 
1
 
MEK1DN, respectively) and MKK6
(pCS2
 
1
 
MKK6act and pCS2
 
1
 
MKK6DN, respectively). A PKB(Akt)
cDNA was amplified by reverse transcriptase PCR using human placental 
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mRNA as a template, and the accuracy of its sequence was checked. A
PKB(Akt) cDNA thus obtained was inserted downstream of the cytomeg-
alovirus promoter of pCS2
 
1
 
c-Myc–tagged (MT) (pCS2
 
1
 
MT-PKB(Akt)wt
for expression of c-Myc–tagged wild-type PKB(Akt). The expression plas-
mid of c-Myc–tagged constitutively active form of PKB(Akt), pCS2
 
1
 
MT-
PKB(Akt)act, was constructed as described previously (Dario et al. 1996).
 
Cell Culture
 
Isolated gizzard SMCs were prepared from 15-d-old chick embryo giz-
zards as described elsewhere (Hayashi et al., 1998), and cultured on lami-
nin-coated six-well plates with the indicated growth factors under kinase
inhibited or stimulated conditions. Vascular SMCs were isolated from
5-wk-old rat aortae by enzyme-disperse methods as follows. Aortae were
dissected under sterile conditions, minced well with scissors, and incu-
bated at 37
 
8
 
C in 0.1% collagenase for 30 min, followed by incubation in
the mixtures of 0.07% collagenase and 0.03% elastase for 90 min. Dis-
persed single cells were separated from undigested tissues by filtration,
and were collected by centrifugation. The cells thus obtained were washed
twice with growth factor–free basal medium (DME supplemented with
0.2% BSA), and were cultured in the medium containing IGF-I or PDGF-
BB on laminin-coated culture plates. Treatment with specific inhibitors
for ERK kinase (MEK1), PD98059 and/or for p38MAPK, SB203580, was
performed as follows: gizzard or vascular SMCs were preincubated for 1 h
in growth factor–free basal medium (DME supplemented with 0.2%
BSA) containing the indicated amounts of inhibitors, and then stimulated
with medium containing the indicated growth factors with or without in-
hibitors.
Ligand-induced contractility of cultured SMCs was monitored as fol-
lows. The SMCs were cultured under indicated conditions for 3 d, and
then washed with PBS, followed by stimulation with basal culture medium
containing 1 mM carbachol for 1 min. Contractility of cultured SMCs was
observed with an Olympus microscope, and the same fields before and af-
ter carbachol treatment were photographed.
 
Northern Blotting
 
2 
 
m
 
g of total RNA from precultured or cultured SMCs under the indicated
conditions were separated on 1.0% agarose-formaldehyde denaturing
gels, and then transferred to nylon membranes. A caldesmon cDNA
(GenBank M28417) fragment (nucleotides 286 to 810) and a calponin
cDNA (GenBank M63559) fragment (nucleotides 1 to 867) were used as
probes to monitor the expression of respective mRNAs. This caldesmon
cDNA fragment, which contains parts of exons 2 and 3a is a common
probe for the 
 
h- 
 
and 
 
l-
 
caldesmons (Hayashi et al., 1991; Hayashi et al.,
1992). In our previous studies using specific probes for 
 
h-
 
 or 
 
l-
 
caldesmon,
we demonstrated that the full lengths of 
 
h-
 
 and 
 
l-
 
caldesmon mRNAs are
4.8 and 4.1 kb, respectively (Kashiwada et al., 1997; Obata et al., 1997).
Probes were labeled with 
 
32
 
P on the antisense strands and used for hybrid-
ization under the following conditions: 42
 
8
 
C for 16 h in 50% formamide,
6
 
3
 
 
 
SSC, 10
 
3
 
 
 
Denhardt’s solution (1
 
3
 
 
 
Denhardt’s solution is 0.02% poly-
vinylpyrrolidone and 0.02% BSA), 0.5% SDS, and 0.5 mg/ml denatured
herring sperm DNA. The blots were washed in 0.1
 
3 
 
SSC containing 0.1%
SDS at 52
 
8
 
C, and visualized by autoradiography. To quantify the amount
of RNA loaded, ribosomal RNAs were stained with 0.02% methylene
blue.
 
Immunoblotting
 
Total protein of the cell lysates from SMC cultures was separated by SDS-
PAGE and transferred to nitrocellulose membranes. Detection of target
proteins on the membranes was performed using an ECL Western blot-
ting detection kit (Amersham Pharmacia Biotech) with the indicated
polyclonal antibodies.
 
PI3-K Assay
 
Phospholipid mixtures (2 mg/ml) containing phosphatidylinositol (PI) and
phosphatidylserine (PS) were dried under a stream of nitrogen, and soni-
cated in 10 mM Hepes (pH 7.4) in a bath sonicator at 0
 
8
 
C for 15 min. 10 
 
m
 
l
of the resulting vesicles (PI/PS) were used as a substrate for PI3-K. The
preparation of cell extracts and immunoprecipitation for PI3-K were per-
formed at 4
 
8
 
C. The cultured cells were washed three times with ice-cold
PBS, and then lysed in 550 
 
m
 
l of lysis buffer (20 mM Tris-HCl [pH 7.5],
137 mM NaCl, 1 mM MgCl
 
2
 
, 1 mM CaCl
 
2
 
, 1% NP-40, 50 mM NaF, 1 mM
Na
 
3
 
VO
 
4
 
, 50 
 
m
 
g/ml PMSF, 1 
 
m
 
g/ml leupeptin, and 1 
 
m
 
g/ml pepstatin). After
 
gentle shaking for 30 min, the cell extracts were obtained by centrifuga-
tion in a microfuge at 13,000 rpm for 5 min. The amount of PI3-K p85 sub-
unit in the cell extracts was determined by Western blotting using antise-
rum against the PI3-K p85 subunit. The extracts containing equal amounts
of PI3-K p85 subunit were precleaned with control rabbit IgG coupled
protein A–Sepharose for 30 min. The PI3-K was immunoprecipitated with
antiserum against the PI3-K p85 subunit followed by protein A–Seph-
arose. The immunoprecipitates were washed twice with lysis buffer, twice
with 100 mM Tris-HCl (pH 7.5), 0.5 M LiCl, 1 mM DTT, and 0.2 mM
Na
 
3
 
VO
 
4
 
, and three times with 10 mM Tris-HCl (pH 7.5), 100 mM NaCl,
1 mM DTT, and 0.2 mM Na
 
3
 
VO
 
4
 
. All washes were performed at 4
 
8
 
C. The
reaction mixtures (50 
 
m
 
l), containing the immunoprecipitates in 20 mM
Tris-HCl (pH 7.5), 50 mM NaCl, 5 mM MgCl
 
2
 
, 0.5 mM EGTA, 10 
 
m
 
M
ATP, 5 
 
m
 
Ci 
 
g
 
-[
 
32
 
P]ATP, and 20 
 
m
 
g of PI/PS were incubated at 30
 
8
 
C for 10
min. The reactions were terminated and the lipids were extracted by the
addition of CHCl
 
3
 
/MeOH (1:2). The mixture was then vortexed and
cleared by centrifugation. The extracted products were separated by thin-
layer chromatography in a developing solution composed of CHCl
 
3
 
/
MeOH/4 M NH
 
4
 
OH (9:7:2). The production of phosphatidylinositol-
3-phosphate was detected by autoradiography.
 
Other Protein Kinase Assays
 
Cell lysis buffers were as follows: 50 mM Tris-HCl (pH 7.5), 120 mM
NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 50 mM NaF, 1 mM
Na
 
3
 
VO
 
4
 
, 10 mM 
 
b
 
-glycerophosphate, 50 
 
m
 
g/ml PMSF, 1 
 
m
 
g/ml leupeptin,
and 1 
 
m
 
g/ml pepstatin for the ERK and PKB(Akt) assays; 20 mM Tris-
HCl (pH 7.5), 10% glycerol, 1 mM DTT, 120 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 1% Triton X-100, 50 mM NaF, 1 mM Na
 
3
 
VO
 
4
 
, 10 mM 
 
b
 
-glycero-
phosphate, 50 
 
m
 
g/ml PMSF, 1 
 
m
 
g/ml leupeptin, and 1 
 
m
 
g/ml pepstatin for
the JNK assays; and 20 mM Tris-HCl (pH 7.5), 50 mM NaCl, 5 mM
EDTA, 1% Triton X-100, 50 mM NaF, 2 mM Na
 
3
 
VO
 
4
 
, 10 mM 
 
b
 
-glycero-
phosphate, 50 
 
m
 
g/ml PMSF, 1 
 
m
 
g/ml leupeptin, and 1 
 
m
 
g/ml pepstatin for
the p38MAPK assays. The cell extracts were immunoprecipitated with
specific antibodies against individual protein kinases, and the immunopre-
cipitates were washed thoroughly with their lysis buffers and then kinase
assay buffers, and incubated with their respective substrates and 5 
 
m
 
Ci
 
g
 
-[
 
32
 
P]ATP for 30 min at 30
 
8
 
C. The reaction products were analyzed by
15% SDS-PAGE. Reaction mixtures for the kinase assays were as fol-
lows: 50 mM Tris-HCl (pH 7.5), 10 mM MgCl
 
2
 
, 1 
 
m
 
M protein kinase A
inhibitor, 1 mM DTT, and 25 
 
m
 
g histone H2B for the PKB(Akt) assay;
50 mM Tris-HCl (pH 7.5), 10 mM MgCl
 
2
 
, 1 
 
m
 
M protein kinase A inhibi-
tor, 1 mM DTT, and 25 
 
m
 
g myelin basic protein (MBP) for the ERK assay;
50 mM Tris-HCl (pH 7.5), 10 mM MgCl
 
2
 
, 1 
 
m
 
M protein kinase A inhibitor,
1 mM DTT, 1 mM Na
 
3
 
VO
 
4
 
, and 1 
 
m
 
g GST-Jun (1-79) for the JNK as-
say; and 20 mM Hepes (pH 7.4), 20 mM MgCl
 
2
 
, 20 mM 
 
b
 
-glycerophos-
phate, 1 
 
m
 
M protein kinase A inhibitor, 2 mM DTT, and 1 
 
m
 
g GST-ATF2
(1-96) for the p38MAPK assay.
 
Promoter Analysis and Transfection
 
The caldesmon promoter activity was analyzed using the chloramphenicol
acetyltransferase (CAT) construct, GP3CAT, according to the method
described previously (Yano et al., 1995; Obata et al., 1997). The SMCs
prepared as described above were seeded onto laminin-coated six-well
plates, and cultured in the indicated medium for 1 or 3 d. Transfection was
carried out using Trans IT™-LT1, polyamine transfection reagents (Pan
Vera Corporation). Complex mixtures composed of 10 
 
m
 
g of trans IT™-
LT1 reagent and 2 
 
m
 
g of GP3CAT, 1 
 
m
 
g of control plasmid carrying the
luciferase gene under the Rous sarcoma virus (RSV) promoter (RSV-
luciferase), and 1 
 
m
 
g of either control expression plasmid (pCMV5,
pCS2
 
1
 
, or pCS2
 
1
 
MT), expression plasmid carrying a c-Myc–tagged con-
stitutively active form of PI3-K p110
 
a
 
 subunit, a c-Myc–tagged wild-type
or a constitutively active form of PKB(Akt) (pCMV5p110
 
a
 
act, pCS2
 
1
 
MT-PKB(Akt)wt or pCS2
 
1
 
MT-PKB(Akt)act), or either or both of ex-
pression vectors carrying constitutively active and dominant-negative
forms of MEK1 (pCS2
 
1
 
MEK1act and pCS2
 
1
 
MEK1DN) and MKK6
(pCS2
 
1
 
MKK6act and pCS2
 
1
 
MKK6DN), were added to the cells in Opti
minimum Eagle’s medium (GIBCO BRL). After a further 4-h incubation,
the medium was replaced with DME supplemented with 0.2% BSA plus 2
ng/ml IGF-I or 20 ng/ml PDGF-BB, and the transfected cells were har-
vested 48 h later. Standardization of transfection efficiency was performed
by measuring luciferase activity as described previously (Yano et al., 1995;
Obata et al., 1997). The cell extracts containing equal amounts of lu-
ciferase activity were used for the CAT assay. The transfection experi-
ments were repeated at least three times on duplicate cultures with two or 
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three different plasmid preparations. The CAT activities were quantified
by Scanning Imager (Molecular Dynamics).
The effects of forced expression of MEK1 and MKK6 in cultured
SMCs were analyzed as follows. The indicated amounts of control expres-
sion plasmid and either or both of expression plasmids carrying active or
dominant-negative MEK1 and MKK6 were transfected into cultured
SMCs together with 1 mg of a reporter plasmid carrying the b-galactosi-
dase gene downstream from the SV-40 early promoter. Total RNA was
isolated from the transfected cells and the expression levels of caldesmon
and calponin mRNAs were analyzed by Northern blotting as described
above. Transfection efficiencies were determined by staining for b-gal-
actosidase activity from the reporter plasmid using 5-bromo-4-chloro-
3-indolyl-b-D-galactoside (X-gal) as a substrate.
Expression of Epitope-tagged Kinases and
Kinase Assays
Transfection was carried out as described above in Promoter Analysis and
Transfection. In the cases of PI3-K and PKB(Akt) assays, SMCs were
transfected with 3 mg of respective expression plasmids of constitutively
active form of c-Myc–tagged PI3-K p110a subunit, pCMV5p110aact, or
wild-type or constitutive active form of c-Myc–tagged PKB(Akt),
pCS21MT-PKB(Akt)wt or pCS21MT-PKB(Akt)act. Two micrograms
of expression plasmid of each Flag-tagged ERK2 or Flag-tagged
p38MAPK was cotransfected with 2 mg of either expression plasmid of ac-
tive or dominant-negative MEK1 or MKK6, or control plasmid. In both
cases, SMCs were cultured under nonstimulated conditions after transfec-
tion. 2 d later, SMCs were stimulated under indicated conditions. The cell
extracts containing the equal amounts of proteins were precleaned with
control mouse IgG coupled protein G–Sepharose for 30 min and immuno-
precipitated with monoclonal antibody against c-Myc or Flag followed by
protein G–Sepharose. The kinase activities were determined as described
above in PI3-K assay and other protein kinase assays.
Characterization of Conditioned Medium
Conditioned medium obtained from SMCs transfected with both expres-
sion plasmids carrying active MEK1 and MKK6 was filtered through a
0.22-mm membrane. The conditioned medium was heated to 1008C for 15
min or treated with trypsin (30 mg/ml) for 3 h at 308C, followed by the ad-
dition of trypsin inhibitor at a 10-fold excess. The heat- or trypsin-treated
conditioned medium was dialyzed against DME supplemented with 0.2%
BSA at 48C for 16 h, and adjusted to the concentration of IGF-I to 2 ng/ml.
The SMCs were cultured in these medium for 3 d. Heparin–Sepharose af-
finity chromatography was carried out as follows. One ml of 50% slurry of
heparin–Sepharose (Amersham Pharmacia Biotech) equilibrated with
PBS was added to 20 ml of the conditioned medium and gently agitated
for 5 h at 48C. The mixture was poured over a 1-ml Prep Column (Bio-
Rad Labs.), and the follow through fraction (non–heparin-binding) was
collected. The column was rinsed with 10 vol of PBS and eluted stepwise
with 1 ml of PBC containing NaCl (0.5, 1.0, and 1.5 M). Each fraction was
collected and desalted by dialysis against DME supplemented with 0.2%
BSA through a membrane of 3-kD cutoff (Spectrum). Aliquots of each
fraction were diluted (1:4) with DME supplemented with 0.2% BSA and
then added to SMC cultures. Treatment with specific inhibitor of EGF re-
ceptor kinase, AG1478, was performed as follows: SMCs cultured for 2 d
under IGF-I–stimulated conditions were preincubated for 1 h in DME
supplemented with 0.2% BSA containing 1 mM AG1478, and then stimu-
lated with the conditioned medium containing the same concentration of
this drug for 3 d. Total RNAs from cultured SMCs were extracted and the
expression patterns of caldesmon and calponin mRNAs were analyzed by
Northern blotting. Control medium was obtained from culture superna-
tant of SMCs transfected with expression plasmid alone.
Results
Different Downstream Signaling Pathways Triggered by 
PDGF-BB, bFGF, EGF, and IGF-I
We have recently established a novel culture system of
gizzard SMCs in which they maintain a differentiated
phenotype for a long culture period. Of growth factors and
cytokines examined, IGF-I is the most potent for main-
taining the differentiated SMC phenotype as defined by
the expression of SMC-specific molecular markers, cell
morphology, and function (Hayashi et al., 1998). On the
other hand, PDGF-BB, bFGF, and EGF potently induce
SMC de-differentiation (Fig. 1). In 3- and 5-d–cultured
SMCs stimulated with PDGF-BB, bFGF, or EGF, h-cal-
desmon mRNA converts to l-caldesmon mRNA, and total
h- and l-caldesmon mRNAs decrease to 20% of the levels
Figure 1. Effects of PDGF-BB, bFGF, EGF, and IGF-I on a phe-
notype of cultured gizzard SMCs. (A) Expression of caldesmon
mRNAs (top panel; h-caldesmon mRNA [h-CaD, 4.8 kb] and
l-caldesmon mRNA [l-CaD, 4.1 kb]) and calponin mRNA (mid-
dle panel; 1.8 kb) in SMCs stimulated with indicated growth fac-
tors. The bottom panel shows the 28S rRNA stained by methy-
lene blue. Gizzard SMCs were cultured on laminin-coated plates
in DME supplemented with 0.2% BSA for 24 h, and then stimu-
lated with the same medium containing PDGF-BB (20 ng/ml),
bFGF (10 ng/ml), EGF (10 ng/ml), or IGF-I (2 ng/ml) for 3 or 5 d.
Caldesmon and calponin mRNAs in freshly isolated SMCs (Pre)
and cultured SMCs under various conditions were analyzed by
Northern blotting. (B) Comparison of cell morphology of SMCs
under PDGF-BB, bFGF, EGF, or IGF-I–stimulated conditions
for 5 d. The results are shown from four independent experi-
ments.Hayashi et al. Signals Regulating Smooth Muscle Cell Phenotype 731
seen in precultured SMCs. Calponin mRNA is also down-
regulated to a negligible level (Fig. 1 A). However, the lev-
els of h-caldesmon and calponin mRNAs in cultured
SMCs under IGF-I–stimulated conditions are identical
with those seen in precultured cells (Fig. 1 A). Similar re-
sults are obtained using a- and b-tropomyosins (Kashi-
wada et al., 1997) and a1 integrin (Obata et al., 1997),
which are also SMC-specific molecular markers (data not
shown). With regard to cell morphology and function, cul-
tured SMCs under IGF-I–stimulated conditions showed a
spindle-like shape, formed a meshwork structure, and dis-
played carbachol-induced contraction. In contrast, SMCs
stimulated with PDGF-BB, bFGF, or EGF showed a fi-
broblast-like shape and lost the contractility (Figs. 1 B and
4), indicating that PDGF-BB, bFGF, and EGF are potent
factors for inducing SMC de-differentiation.
Our previous studies revealed that the PI3-K/PKB(Akt)
pathway triggered by IGF-I plays a critical role in main-
taining the differentiated SMC phenotype (Hayashi et al.,
1998). To investigate the downstream signaling pathways
involving in SMC de-differentiation triggered by PDGF-
BB, bFGF, or EGF, we analyzed several kinases including
ERK, JNK, p38MAPK, PI3-K, and PKB(Akt). PDGF-
BB, bFGF, and EGF all activated ERK (Fig. 2 A) and
p38MAPK (Fig. 2 C). Their maximum activations were
found at 10 min after stimulation. bFGF and EGF also ac-
tivated JNK, whereas PDGF-BB did not (Fig. 2 B). IGF-I
had no effect on ERK (Fig. 2 A), JNK (Fig. 2 B), and
p38MAPK (Fig. 2 C). These data suggest that growth fac-
tors inducing SMC de-differentiation coordinately activate
the ERK and p38MAPK pathways.
As demonstrated previously (Hayashi et al., 1998), IGF-I
potently activated PI3-K (Fig. 2 D) and PKB(Akt) (Fig. 2
E); the maximum activation of PI3-K was achieved at 10
min after IGF-I stimulation and this activation reduced
thereafter, while the activation of PKB(Akt) by IGF-I (2
ng/ml) lasted for more than 180 min. The activation of
PI3-K and PKB(Akt) by IGF-I was suppressed by specific
PI3-K inhibitors, wortmannin or LY249002 (data not
shown), indicating that the PKB(Akt) activation exclu-
sively depends on the PI3-K activity. No significant activa-
tion of PI3-K and PKB(Akt) was observed in SMCs stimu-
lated by either bFGF or EGF (Fig. 2, D and E). Among
the three growth factors inducing SMC de-differentiation,
PDGF-BB was the only one that could activate PI3-K and
PKB(Akt) (Fig. 2, D and E). The PKB(Akt) activation by
PDGF-BB was more potent than that by IGF-I at 15 min
after growth factor stimulation, whereas this activation
was transient, but retained at a substantial level for 180
min. By contrast, the PKB(Akt) activation by IGF-I was
sustained at a high level for more than 180 min. These re-
sults suggest the possibility that in addition to PI3-K,
Figure 2. Characterization of the downstream signaling pathways triggered by PDGF-BB, bFGF, EGF, and IGF-I in SMCs. Gizzard
SMCs were plated on laminin and cultured in DME supplemented with 0.2% BSA for 24 h, and then stimulated with the following
growth factors for the indicated times: 20 ng/ml PDGF-BB, 10 ng/ml bFGF, 10 ng/ml EGF, 2 ng/ml IGF-I, or 10 mg/ml anisomycin. The
cells were lysed and the extracts were assayed for the kinase activities of ERK (A), JNK (B), p38MAPK (C), PI3-K (D), and PKB(Akt)
(E) as described in Materials and Methods. The left-hand lanes (0 min) in A–E were the controls without stimulation. Immunoblottings
were performed to determine the amounts of kinase proteins in the cell lysates. The top and middle panels show the results of kinase as-
says and immunoblottings (IB), respectively. The relative activation rates normalized to respective control are shown in the bottoms.
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PDGF-BB activates PKB(Akt) mediated through another
unknown cascade.
Dual Function of PDGF-BB on Gizzard
SMC Phenotype
It is curious that PDGF-BB, which is a potent factor induc-
ing SMC de-differentiation (Fig. 1), triggered the dual sig-
naling pathways mediated through both PI3-K/PKB(Akt)
and two MAPKs, ERK and p38MAPK (Fig. 2). To sim-
plify the PDGF-BB–triggered signaling pathways, we ex-
amined the effects of specific MAPK inhibitors, PD98059
for ERK kinase (MEK1) and SB203580 for p38MAPK,
on the PDGF-BB–stimulated SMC phenotype. Either
PD98059 or SB203580 specifically inhibited the PDGF-
BB–induced activation of ERK or p38MAPK, respec-
tively, to near basal levels (Fig. 3 A), but had no effect on
PI3-K and PKB(Akt) (data not shown). Treatment with
either PD98059 or SB203580 only slightly suppressed
the PDGF-BB–induced isoform conversion of caldesmon
mRNA and downregulation of caldesmon and calponin
mRNAs (Fig. 3 B). However, simultaneous treatment with
both drugs strongly suppressed the PDGF-BB–induced
SMC de-differentiation as monitored by the expression of
caldesmon and calponin mRNAs (Fig. 3 B). In addition to
these molecular events, both drugs could also rescue the
morphological alteration from a spindle-like shape to a fi-
broblast-like shape change and a loss of contractility in-
duced by PDGF-BB (Fig. 4). As a control, treatment with
individual drug resulted in less significant effect on cell
morphology and function. Table I shows the effects of
PD98059 and/or SB203580 on carbachol-stimulated con-
tractility of SMCs under various culture conditions. Fur-
ther, both drugs only slightly delayed the induction of
SMC de-differentiation by bFGF or EGF, but did not pre-
vent SMC de-differentiation (data not shown).
Promoter analyses of the caldesmon gene further sup-
port these findings (Fig. 5). We used the caldesmon pro-
moter/CAT construct, GP3CAT, which produces the high
promoter activity in differentiated SMCs (Yano et al.,
1995). The promoter activity in SMCs stimulated by
PDGF-BB reduced to 30% of that by IGF-I (Fig. 5 C).
Even under PDGF-BB–stimulated conditions, inhibition
of both the ERK and p38MAPK pathways by their spe-
cific inhibitors or the forced expression of active PI3-K
(Fig. 5 A) or active PKB(Akt) (Fig. 5 B) could protect
such reduction (Fig. 5 C). These results suggest that
PDGF-BB displays the dual function in maintaining the
differentiated SMC phenotype mediated through the PI3-
K/PKB(Akt) pathway and inducing SMC de-differentia-
tion by the ERK and p38MAK pathways. Thus, changes in
the balance between the strengths of the PI3-K/PKB(Akt)
pathway and the ERK and p38MAPK pathways would de-
termine the SMC phenotype.
Direct Involvement of ERK and p38MAPK Inducing 
Gizzard SMC De-differentiation
The MAPK signaling cascades are involved in a variety of
cell functions (Force and Bonventre, 1998). Dual phos-
phorylation on Thr and Tyr within the Thr-Xaa-Tyr motif
catalyzed by MAPK kinases is essential for MAPK activa-
tion (Davis, 1994). MEK1 and MKK6 are specific upstream
kinases for ERK and p38MAPK, respectively (Cohen,
1997). To investigate the direct involvement of ERK and
p38MAPK in SMC de-differentiation, we examined the ef-
fects of active or dominant-negative MEK1 and/or MKK6
on the caldesmon promoter activity in SMCs under IGF-
I–stimulated conditions. We determined the respective
MAPK kinase activity by in vitro kinase assay (Fig. 6 A).
In this experiment, expression plasmids carrying active
or dominant-negative MAPK kinases were cotransfected
with expression plasmid carrying Flag-tagged ERK or
Flag-tagged p38MAPK into cultured SMCs, and Flag-
tagged proteins were immunoprecipitated from the cell ly-
sates with anti-Flag monoclonal antibody. The ERK or
p38MAPK activities were potently enhanced in SMCs
cotransfected with active MEK1 or MKK6 under nonstim-
ulated or PDGF-BB–stimulated conditions (Fig. 6 A, a
Figure 3. The effect of blocking the ERK and p38MAPK signal-
ings on the expression of caldesmon and calponin mRNAs in giz-
zard SMCs under PDGF-BB–stimulated conditions. (A) Inhibi-
tion of PDGF-BB–induced activation of ERK and p38MAPK by
PD98059 and/or SB203589. The SMCs plated on laminin were
cultured in DME supplemented with 0.2% BSA for 24 h, and
then pretreated with either PD98059 (30 mM) or SB203580 (20 mM),
or both drugs for 1 h, followed by PDGF-BB (20 ng/ml) stimula-
tion in the presence of vehicle alone or indicated drugs for 10
min. The representative data are shown from three independent
experiments. (B) The expression of caldesmon and calponin
mRNAs was analyzed by Northern blotting as shown in Fig. 1 A.
Total RNAs were isolated from 3-d–cultured SMCs plated on
laminin under indicated conditions, and then analyzed by North-
ern blotting using caldesmon and calponin cDNA fragments as
probes. Culture conditions were as follows: IGF-I (2 ng/ml),
PDGF-BB (20 ng/ml), PDGF-BB (20 ng/ml) in the presence of
either PD98059 (30 mM) or SB203580 (20 mM) or both drugs.
The results are shown from four independent experiments.
Table I. Effects of MAPK Inhibitors on the Contractile 
Response of Cultured SMCs
Culture conditions Contracted cells
%
IGFI 92.9 6 2.0
PDGF-BB 0
PDGF-BB 1 PD 1.8 6 0.7
PDGF-BB 1 SB 9.0 6 1.0
PDGF-BB 1 PD/SB 92.4 6 3.1Hayashi et al. Signals Regulating Smooth Muscle Cell Phenotype 733
and b). Even when SMCs were stimulated by PDGF-BB,
their enhancements were strongly abolished by the forced
expression of dominant-negative MEK1 or MKK6 (Fig. 6
A, a and b). The expressions of active and dominant-nega-
tive MEK1 or MKK6 proteins were confirmed by immu-
noblotting (data not shown). The caldesmon promoter
activity in differentiated SMCs under IGF-I–stimulated
conditions was analyzed by the forced expression of active
Figure 4. Rescue of PDGF-
BB–induced SMC de-differ-
entiation by blocking the
ERK and p38MAPK path-
ways. Gizzard SMCs plated
on laminin were stimulated
with 2 ng/ml IGF-I (a and d),
20 ng/ml PDGF-BB (b and
e), or 20 ng/ml PDGF-BB in
the presence of both PD98059
(30  mM) and SB203580 (20
mM) (c and f) for 3 d. Ligand-
induced contractility was
monitored by the addition of
carbachol (1 mM) for 1 min.
Photographs show cultured
SMCs before (a, b, and c) and
after (d, e, and f) carbachol
treatment. The data are pre-
sented from five independent
experiments.
Figure 5. Regulation of the caldesmon promoter
activity mediated through the PI3-K/PKB(Akt)
pathway and the ERK and p38MPAK pathways.
(A) The PI3-K activity in nonstimulated SMCs
transfected with control plasmid (pCMV5) and
expression plasmid of c-Myc–tagged active PI3-K
p110a subunit, pCMV5p110aact (PI3-Kact).
Gizzard SMCs transfected with indicated plas-
mids were cultured under nonstimulated condi-
tions, and the PI3-K activity was determined by
immunoprecipitation with anti–c-Myc mono-
clonal antibody, followed by in vitro kinase as-
says as described in Materials and Methods. (B)
The PKB(Akt) activity in SMCs transfected
with control plasmid, pCS21MT, expression
plasmid of c-Myc–tagged wild-type PKB(Akt),
pCS21MT-PKB(Akt)wt, or expression plasmid
of c-Myc–tagged active PKB(Akt), pCS21MT-
PKB(Akt)act. The SMCs were cultured under
nonstimulated conditions for 2 d after transfec-
tion, and then half of the cultures were stimu-
lated by 2 ng/ml IGF-I with or without treatment
of 20 mM LY294002. PKB(Akt) assays were car-
ried out as described above. In A and B, the top
and bottom panels are the results of kinase assay
and immunoblotting (IB) to determine the amounts of kinase proteins in the cell lysates, respectively. The kinase activities are shown
from three independent experiments. (C) Effects of PDGF-BB– or IGF-I–triggered signalings on the caldesmon promoter activity. The
promoter construct of caldesmon, GP3CAT, was transfected into 3-d–cultured SMCs under the following conditions: DME supple-
mented with 0.2% BSA alone or BSA plus 20 ng/ml PDGF-BB. The GP3CAT (2 mg) was cotransfected with RSV-luciferase (1 mg) and
control plasmid (1 mg), expression plasmid of c-Myc–tagged active PI3-K p110a (PI3-Kact, 1 mg), or expression plasmid of c-Myc–
tagged active PKB(Akt) (PKB(Akt)act, 1 mg), respectively. After transfection, SMCs were stimulated with 2 ng/ml IGF-I, 2 ng/ml IGF-I
plus 20 mM LY294002, 20 ng/ml PDGF-BB, or 20 ng/ml PDGF-BB plus PD98059 (30 mM) and SB203580 (20 mM). The promoter activity
was assayed at 48 h after transfection as described in Materials and Methods. The relative promoter (CAT) activities were normalized
to the activity in culture SMCs under IGF-I–stimulated conditions, which was defined as 100%. Each value represents the average 6
SD of three independent experiments. A promoterless control CAT plasmid (pUC0CAT) did not show detectable CAT activity under
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or dominant-negative MAPK kinases (Fig. 6 B). The pro-
moter activity was not affected by either or both domi-
nant-negative MEK1 and/or MKK6. Transfection with ei-
ther active MEK1 or MKK6 significantly reduced the
caldesmon promoter activity, while cotransfection with
both active kinases further suppressed the promoter activ-
ity. Since the SV-40 promoter was not affected by the
forced expression of MEK1 and/or MKK6 (data not
shown), suppression of the caldesmon promoter activity
by active MEK1 and MKK6 was specific. These results in-
dicate that the ERK and p38MAPK pathways are directly
involved in the induction of SMC de-differentiation.
Detection of De-differentiation-inducing Factor(s) from 
Gizzard SMCs Cotransfected with Active MEK1
and MKK6
We further examined the effects of active and dominant-
negative MEK1 or MKK6 on the endogenous expression
of caldesmon and calponin mRNAs and on cell morphol-
ogy. Transfection with either active kinase alone or co-
transfection with dominant-negative kinases had less sig-
nificant effects on caldesmon and calponin mRNAs in
2- or 4-d–cultured SMCs (Fig. 7 A, lanes 1, 2, 4–8, and 10–
12). Even under IGF-I–stimulated conditions, cotransfec-
tion of active MEK1 and MKK6 potently induced isoform
conversion of caldesmon mRNA and downregulation of
caldesmon and calponin mRNAs. These changes pro-
gressed during culture; the endogenous expressions of
caldesmon and calponin mRNAs in 4-d–cultured SMCs
after cotransfection were comparable to those seen in
4-d–cultured SMCs stimulated by PDGF-BB (Fig. 7 A,
lanes 3, 9, and 13). These results indicate that after
cotransfection with active MEK1 and MKK6, almost all of
cultured SMCs alter their phenotype to de-differentiation.
To compare transfection efficiency and cell morphology,
cultured SMCs stimulated by IGF-I were transfected with
control plasmid (Fig. 7 B, a) or both expression plasmids
carrying active MEK1 and MKK6 (Fig. 7 B, b) together
with b-galactosidase expression plasmid. As revealed by
b-galactosidase staining, transfection efficiencies were
z25%. The SMCs transfected with control vector re-
mained to show a spindle-like shape (Fig. 7 B, a). In the
case of SMCs cotransfected with active MEK1 and MKK6,
all of the b-galactosidase-stained and -unstained cells con-
verted from a spindle-like shape to a fibroblast-like shape
(Fig. 7 B, b). The transfection efficiency of both active
MEK1 and MKK6 was correlated with SMC-specific
marker gene expression and cell morphology (Fig. 7, C
and D). These data suggest that SMCs cotransfected with
active MEK1 and MKK6 secrete some factor(s) which in-
duces de-differentiation of surrounding normal SMCs.
To further characterize such a factor(s), conditioned
medium (CM1) obtained from SMCs cotransfected with
expression plasmids carrying active MEK1 and MKK6 was
prepared. Fig. 8 A shows the expression of caldesmon and
calponin mRNAs in 3-d–cultured SMCs stimulated with
the conditioned medium. Even when SMCs were stimu-
lated by IGF-I, the conditioned medium potently induced
isoform conversion of caldesmon mRNA and downregula-
tion of caldesmon and calponin mRNAs (Fig. 8 A, lane 1),
whereas control medium (CM2) obtained from SMCs
Figure 6. Inhibition of the caldesmon pro-
moter activity in gizzard SMCs by the forced
expression of active MEK1 and MKK6. (A)
Effects of active and dominant-negative
MEK1 or MKK6 on the kinase activities of
ERK (a) and p38MAPK (b) in cultured
SMCs under non-stimulated and PDGF-BB–
stimulated conditions. The SMCs were
cotransfected with 2 mg each of expression
plasmid of active or dominant-negative
MEK1 and/or MKK6 or control plasmid to-
gether with 2 mg Flag-tagged ERK2 or Flag-
tagged p38MAPK. The SMCs were cultured
under nonstimulated conditions for 2 d, and
half of the cultures were stimulated with 20
ng/ml PDGF-BB for 10 min. The cells were
lysed and subjected to kinase assays after im-
munoprecipitation with anti-Flag monoclonal
antibody. The top and bottom panels are the
results of kinase assay and immunoblotting
(IB) to determine the amounts of Flag-tagged
kinase proteins in the cell lysates. The repre-
sentative data are from two independent ex-
periments. (B) Effects of the forced expres-
sion of active or dominant-negative MEK1 and/or MKK6 on the caldesmon promoter activity. The SMCs were cotransfected with
GP3CAT (2 mg), RSV-luciferase (1 mg), and either or both expression vectors carrying active or dominant-negative MEK1 and/or
MKK6 (1 mg). The total amounts of transfected plasmids were adjusted to 5 mg by the addition of control vector, pCS21. The promoter
activities were determined as described in the legend of Fig. 5. The relative promoter activities were normalized to the activity in cul-
tured SMCs under IGF-I–stimulated conditions without expression vectors carrying MEK1 or MKK6, which was defined as 100%.
Each value represents the average 6 SD of three independent experiments.Hayashi et al. Signals Regulating Smooth Muscle Cell Phenotype 735
Figure 7. Detection of de-differentiation–inducing factor(s) from SMCs cotrans-
fected with active MEK1 and MKK6. (A) Effects of the forced expression of active
or dominant-negative MEK1 and/or MKK6 on the endogenous expression of caldes-
mon and calponin mRNAs. Gizzard SMCs were transfected with 1 mg of indicated
expression plasmids, and then cultured under IGF-I–stimulated conditions for 2 d
(lanes 1–5) and for 4 d (lanes 7–11). The total amounts of transfected plasmids
were adjusted to 2 mg by the addition of pCS21. The SMCs were also cultured under
IGF-I–stimulated conditions (2 ng/ml) without transfection for 2 d (lane 6) and 4 d
(lane 12), or under PDGF-BB–stimulated conditions (20 ng/ml) without transfection
for 4 d (lane 13). Caldesmon and calponin mRNAs in cultured SMCs were analyzed
by Northern blotting as shown in Fig. 1 A. (B) Transfection efficiency and compari-
son of cell morphology between SMCs transfected with control plasmid (a) and ex-
pression plasmids carrying active MEK1 and MKK6 (b). The SMCs were transfected
with pCS21 (2 mg) and pSVb-galactosidase (1 mg) (a) or with pCS21MEK1act (1
mg), pCS21MKK6act (1 mg), and pSVb-galactosidase (1 mg) (b), and then cultured
under IGF-I–stimulated conditions. At 4 d after transfection, b-galactosidase activity
was visualized using X-gal as a substrate. (C and D) Dose-dependent effect of trans-
fection with active MEK1 and MKK6 on the SMC phenotype. The SMCs were trans-
fected with the indicated amounts of pCS21MEK1act and pCS21MKK6act
together with pSVb-galactosidase (1 mg), and then cultured for 4 d under IGF-
I–stimulated conditions. Transfection efficiency was increased in increasing amounts
of transfected plasmids as follows: lane 1 in C and top panel in D, ,1%; lane 2 in C
and middle panel in D, 5%; and lane 3 in C and bottom panel in D, 25%. The expres-
sion of caldesmon and calponin mRNAs (C) and cell morphology (D) of transfected
SMCs are shown. The representative data are shown from four (A and B) or three (C
and D) independent experiments.The Journal of Cell Biology, Volume 145, 1999 736
transfected with control plasmid alone did not (Fig. 8 A,
lane 2). Further, the conditioned medium enhanced the
ERK, JNK, and p38MAPK activities (Fig. 8 B). These re-
sults exclude the possibility of retransfection with residual
expression vectors, because MEK1 and MKK6 proteins
derived from expression plasmids were not detected in
cultured SMCs by immunoblotting (data not shown).
Thus, this study revealed that the forced activation of both
ERK and p38MAPK in SMCs induces the secretion of
some factor(s) which initiates de-differentiation of sur-
rounding normal SMCs in a paracrine manner. Heat or
trypsin treatment of the conditioned medium completely
abolished the activity inducing SMC de-differentiation
(Fig. 8, lanes 3 and 4), suggesting that the factor(s) is a pro-
tein in nature. The conditioned medium was further frac-
tionated using a heparin–Sepharose column. The flow
through (non–heparin-binding) fraction retained the po-
tent de-differentiation activity, while the eluted fraction by
0.5, 1.0, and 1.5 M NaCl did not (Fig. 8 A, lanes 5–8).
PDGFs and bFGF show heparin-binding abilities; the
former was eluted with 0.5 M NaCl and the latter with 1.5 M
NaCl (data not shown). By contrast, EGF is known as a
non–heparin-binding growth factor, suggesting a candi-
date for the active protein factor. A specific inhibitor for
EGF receptor kinase, AG1478, only slightly inhibited the
conditioned medium-induced de-differentiation, but this
effect was less significant (Fig. 8 A, lane 9). Therefore, the
active protein factor(s), which induces SMC de-differenti-
ation, in the conditioned medium is considered to be dif-
ferent from PDGFs, bFGF, and EGF.
Signaling Pathways in Regulating the Vascular
SMC Phenotype
To examine whether vascular SMCs could be regulated by
the same signaling pathways as revealed in gizzard SMCs,
we first applied our culture system of gizzard SMCs to vas-
cular SMCs. We isolated rat vascular SMCs by the en-
zyme-disperse method, and cultured them on laminin-
coated plates under IGF-I–stimulated conditions. Because
of difficulty to obtain a lot of cell numbers from rat aortae,
we observed cell morphology and ligand-induced contrac-
tility to determine the vascular SMC phenotype (Fig. 9).
Vascular SMCs could also maintain a spindle shape for
more than 2 weeks under IGF-I–stimulated conditions,
and showed ligand-induced contractility (Fig. 9, a and f). A
blockade of the PI3-K pathway by LY294002 resulted in a
morphological change from a spindle shape to a fibroblast-
like shape and a loss of contractility (Fig. 9, b and g). In-
consistent with the case of gizzard SMCs, PDGF-BB
rapidly induced de-differentiation of vascular SMCs as
monitored by cell morphology and ligand-induced con-
tractility (Fig. 9, c and h). Even under PDGF-BB–stimu-
lated conditions, simultaneous treatment with PD98059
and SB203580 could retain a spindle shape and contractil-
ity (Fig. 9, d and i). As a control, treatment with each drug
individually was less significant effect on the PDGF-BB–
induced de-differentiation (data not shown). Furthermore,
the conditioned medium obtained from gizzard SMCs
transfected with both active MEK1 and MKK6 remark-
ably induced de-differentiation of vascular SMCs (Fig. 9, e
and j). Therefore, these data also suggest that the PI3-
K–mediated signaling pathway plays a vital role in main-
taining a differentiated phenotype of vascular SMCs and
the ERK and p38 MAPK pathways are coordinately in-
volved in de-differentiation of vascular SMCs.
Discussion
Under pathological conditions, phenotype of SMCs can
change from a differentiated state to a de-differentiated
state in vivo and in vitro. During de-differentiation, SMCs
show dramatic and irreversible alterations in their cell
shape, function, and expression of SMC-specific molecular
markers. Long spindle-shaped cells change to fibroblast-
like cells, accompanied by losses in a ligand-induced con-
tractility and SMC-specific molecular marker expression.
Since there has not been a primary culture system avail-
able for SMCs or SMC-derived cell lines in which they can
maintain a fully differentiated phenotype, the intracellular
signaling pathways regulating the SMC phenotype have
not been well characterized. Recently, we established a
novel culture system in which gizzard SMCs can maintain
a differentiated phenotype for a long culture time (Ha-
yashi et al., 1998). In this culture system, IGF-I is the most
potent for maintaining the differentiated SMC phenotype,
Figure 8. Characterization of SMC de-differentiation–induc-
ing  factor(s). (A) Gizzard, SMCs were transfected with
pCS21MEK1act (1 mg) and pCS21MKK6act (1 mg) or with
pCS21 (2 mg), and were cultured for 3 d. Each culture me-
dium  was collected; CM1 from SMCs transfected with
pCS21MEK1act and pCS21MKK6act and CM2 from SMCs
transfected with pCS21. Then, SMCs were cultured under fol-
lowing conditions for 3 d: CM1 (lane 1), CM2 (lane 2), heat-
treated CM1 (lane 3), trypsin-treated CM1 (lane 4), follow
through (lane 5), and eluted (lanes 6–8) fractions of heparin-affin-
ity column chromatography of CM1, or CM1 plus 1 mM AG1478
(lane 9). Caldesmon and calponin mRNAs in cultured SMCs
were analyzed by Northern blotting as shown in Fig. 1 A. (B) Ac-
tivation of ERK, JNK, and p38MAPK by the conditioned me-
dium. Gizzard SMCs were stimulated under the following condi-
tions: nonstimulation (N), CM1 for 10 min, CM2 for 10 min,
PDGF-BB (20 ng /ml) for 10 min (P), or anisomycin (10 mg/ml)
for 30 min (A). Then, the cells were lysed and subjected for ki-
nase assays, ERK (top panel), JNK (middle panel), and
p38MAPK (bottom panel) as described in Materials and Meth-
ods. (A). The data are representative of three (A) or two (B) in-
dependent experiments.Hayashi et al. Signals Regulating Smooth Muscle Cell Phenotype 737
and the IGF-I–triggered signaling pathway, PI3-K/PKB-
(Akt), plays a critical role in this maintenance. Here, we
investigated the signaling pathways inducing SMC de-dif-
ferentiation and compared them with the PI3-K/PKB-
(Akt) pathway.
It has been reported that PDGF, EGF, bFGF, or an-
giotensin II enhance cell proliferation or hypertrophy
through the activation of the ERK signaling cascade in
passaged vascular SMCs (Force and Bonventre, 1998).
MAPKs such as JNK and p38MAPK are also activated in
response to various cellular stresses (Derijard et al., 1994;
Kyrian and Avruch, 1996). Angiotensin II and phenyleph-
rine, which induce acute hypertension, enhance the ERK
and JNK activities in aortic, carotid and femoral arteries
(Xu et al., 1996), and endothelin activates both of these ki-
nases in proliferative airway SMCs (Shapiro et al., 1996).
p38MAPK, ERK, and/or JNK are also activated by bal-
loon injury of carotid arteries (Hu et al., 1997; Pyles et al.,
1997; Larrivee et al., 1998). These findings suggest a close
association of MAPK cascades with smooth muscle disor-
ders. However, the direct involvement of these signaling
cascades in regulating the SMC phenotype has been un-
known. As a first step, we used a novel culture system of
gizzard SMCs and demonstrated that activations of the
PI3-K/PKB(Akt) pathway and the ERK and p38MAPK
pathways are directly involved in maintaining SMC differ-
entiation and inducing SMC de-differentiation, respec-
tively. This conclusion is based on the following findings.
First, the signaling pathways in regulating the phenotypic
determination of gizzard SMCs were distinctly different;
the PI3-K/PKB(Akt) pathway played a critical role in
maintaining the differentiated SMC phenotype (Figs. 2
and 5) and the ERK and p38MAPK pathways triggered by
PDGF-BB, bFGF, and EGF were closely associated with
SMC de-differentiation (Figs. 1 and 2). Second, among the
three growth factors inducing SMC de-differentiation,
PDGF-BB only triggered both the PI3-K/PKB(Akt) path-
way and the ERK and p38MAPK pathways. When both
the MAPK pathways were blocked by their specific inhibi-
tors, PD98059 and SB203580, or when SMCs were trans-
fected with active PI3-K or PKB(Akt), PDGF-BB in turn
initiated to maintain the differentiated SMC phenotype
(Figs. 3–5 and Table I). Third, even when SMCs were cul-
tured under IGF-I–stimulated conditions, the forced acti-
vation of both the MAPK pathways by the coexpression of
active MEK1 and MKK6 potently induced SMC de-differ-
entiation (Fig. 6). Fourth, SMCs cotransfected with active
MEK1 and MKK6 secreted a nondialyzable and heat-
labile protein factor(s), which induced de-differentiation
of surrounding normal SMCs (Figs. 7 and 8). Finally, the
same signaling pathways as described above were ob-
served to be involved in regulating the vascular SMC phe-
notype (Fig. 9).
Since IGF-I enhances the proliferation and migration of
cultured vascular SMCs (Clemmons 1985; Bornfeldt et al.,
1990; Cercek et al., 1990; Delafontaine et al., 1991; Born-
Figure 9. Analyses of signaling pathways in regulating the vascular SMC phenotype. Rat vascular SMCs were cultured on laminin in the
presence of IGF-I (20 ng/ml) for 2 d, and then stimulated with following conditions for 3 d: 20 ng/ml IGF-I (a and f), 20 ng/ml IGF-I plus
20 mM LY294002 (b and g), 20 ng/ml PDGF-BB (c and h), 20 ng/ml PDGF-BB plus PD98059 (30 mM) and SB203580 (20 mM) (d and i),
and the conditioned medium (CM1) from cultured gizzard SMCs transfected with pCS21MEK1act and pCS21MKK6act (e and j).
Ligand-induced contractility was monitored as described in the legend of Fig. 4. Photographs show SMCs before (a–e) and after (f–j)
carbachol treatment. The representative data are shown from five independent experiments.The Journal of Cell Biology, Volume 145, 1999 738
feldt et al., 1994), it has been considered to be an impor-
tant growth factor in the progression of atherosclerosis.
These findings are, however, obtained using passaged
SMCs. In this paper, we demonstrated using a novel
SMC culture system that IGF-I solely triggers the PI3-
K/PKB(Akt) pathway, but not the MAPK pathways (Fig.
2). Further, IGF-I did not affect the proliferation of SMCs
(data not shown). These properties of IGF-I signaling
made it possible to maintain the differentiated SMC phe-
notype for more than 2 wk in primary culture. Since rapa-
mycin had no effect on the differentiated SMC phenotype
under IGF-I–stimulated conditions (Hayashi et al., 1998),
p70 ribosomal S6 kinase (p70S6K) is unlikely to be a down-
stream target of PI3-K/PKB(Akt). Further study is re-
quired to identify the downstream targets of PI3-K/
PKB(Akt) in SMCs. It has been reported that IGF-I and
its downstream signaling, PI3-K/PKB(Akt), play a role in
protection against programmed cell death (Alessi and Co-
hen 1998). We observed neither a significant decrease in
cell numbers nor DNA fragmentation in our SMC cultures
even under nonstimulated conditions or in the presence of
IGF-I neutralizing antibodies (data not shown). There-
fore, cultured SMCs might secrete anti-apoptotic factor(s)
in the absence of IGF-I, and the maintenance of the dif-
ferentiated SMC phenotype by IGF-I would be distinct
from an anti-apoptotic action. In passaged SMCs, IGF-I
enhanced the JNK and p38MAPK activities (data not
shown). These results suggest that the downstream signal-
ings of IGF-I might be modulated during cell passage. Ac-
tually, differentiated SMCs rapidly change their pheno-
type under serum-stimulated conditions (Kashiwada et al.,
1997; Hayashi et al., 1998). Since passaged SMCs do not
represent a stable differentiated state, studies reported
previously might not be able to reveal the IGF-I’s function
and signaling in differentiated SMCs. In this study, we
used SMCs that showed well-characterized and stable phe-
notypes. We analyzed the relationship between the modu-
lation of SMC phenotype and cell proliferation. Although
serum-induced SMC de-differentiation was concomitant
with cell proliferation, other growth factors that trigger
SMC de-differentiation, such as PDGF-BB, bFGF, and
EGF, did not significantly induce SMC proliferation (data
not shown). This result also suggests that SMC de-differ-
entiation is not essentially associated with cell prolifera-
tion.
It has been reported that de-differentiated SMCs pro-
duce and secrete PDGF which further promotes cell pro-
liferation and migration in an autocrine/paracrine manner
(Sjolund et al., 1988). PDGF is also known to promote the
activation of ERK and p38MAPK in passaged SMCs
(Bornfeldt et al., 1994; Pyne and Pyne, 1997). In our cul-
ture system, PDGF-BB triggered the dual signaling path-
ways mediated by PI3-K/PKB(Akt) and two MAPKs,
ERK and p38MAPK. Under these culture conditions,
PDGF-BB stimulation resulted in SMC de-differentiation.
When the two MAPK pathways were blocked by their
specific inhibitors, PD98059 and SB203580, PDGF-BB
stimulation, in turn, initiated to maintain SMC differentia-
tion (Figs. 3 and 4). bFGF and EGF are known to activate
ERK and also to induce proliferation of SMCs (Berrou et al.,
1996; Jones et al., 1997; Yu et al., 1997; Miyamoto et al.,
1998). In our culture system, both growth factors activated
ERK and p38MAPK and potently induced SMC de-dif-
ferentiation (Figs. 1 and 2). However, PD98059 and
SB203580 could not prevent such de-differentiation (data
not shown). This is because the signaling pathway medi-
ated by PI3-K/PKB(Akt) was not activated by bFGF or
EGF (Fig. 2). In the present culture system, bFGF and
EGF also activated JNK, but IGF-I and PDGF-BB did not
(Fig. 2). It is, therefore, unlikely that JNK is involved in
regulating the SMC phenotype. PDGF-BB reduced the
caldesmon promoter activity and this reduction could be
overcome by the forced expression of active PI3-K or
PKB(Akt), or by treatment with both PD98059 and
SB203580 (Figs. 3–5 and Table I). Further, the activation
of ERK and p38MAPK by the forced expression of both
active MEK1 and MKK6 could overcome the PI3-K/
PKB(Akt) pathway triggered by IGF-I, resulting in the in-
duction of SMC de-differentiation (Fig. 6). These data
support our hypothesis that the SMC phenotype would be
determined by the balance between the strengths of the
signaling pathways mediated by PI3-K/PKB(Akt) and by
ERK and p38MAPK.
Curiously, even though the transfection efficiencies of
both expression vectors carrying active MEK1 and MKK6
were only 25%, almost all of SMCs came to de-differenti-
ate as monitored by cell morphology and endogenous
expression of SMC-specific molecular markers (Fig. 7).
These findings indicate that the production and secre-
tion of some de-differentiation-inducing factor(s) occur in
SMCs in which both the ERK and p38MAPK pathways
are constitutively activated. We have not yet identified
such a factor(s), but the conditioned medium from these
cells activated three MAPK pathways (ERK, p38MAPK,
and JNK). The activating factor(s) was a heat-labile, non–
heparin-binding protein factor (Fig. 8). From these bio-
chemical properties (Fig. 8), we excluded the possibility
that PDGF-BB, bFGF, and EGF would be the main factor
inducing SMC de-differentiation in the conditioned me-
dium. Further study is required to identify such a factor(s).
Anyway, this study provides a evidence that only a small
portion of de-differentiated SMCs secretes a protein fac-
tor(s) for the surrounding normal SMCs to be de-differen-
tiated. These findings could be helpful to understand the
progression of smooth muscle disorders such as athero-
sclerosis.
We then applied a culture system of gizzard SMCs to
that of vascular SMCs and investigated the signaling path-
ways in regulating the vascular SMC phenotype (Fig. 9).
Like gizzard SMCs, IGF-I potently maintained a differen-
tiated phenotype of vascular SMCs and a specific PI3-K
inhibitors, LY24002, prevented this IGF-I’s action. Treat-
ment with two MAPK pathway inhibitors, PD98059 and
SB203580, could rescue the PDGF-BB–induced de-differ-
entiation of vascular SMCs. Further, the conditioned me-
dium obtained from gizzard SMCs also induce de-differen-
tiation of vascular SMCs. These results strongly suggest
that a culture system of gizzard SMCs is applicable for that
of vascular SMCs and that the distinct signaling pathways
mediated by PI3-K/PKB(Akt) and two MAPKs are also
involved in the phenotypic determination of vascular
SMCs.
Our results presented here are summarized in Fig. 10.
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required to maintain a differentiated phenotype of visceral
and vascular SMCs, while the activation of ERK and
p38MAPK leads to SMC de-differentiation of both types
of SMCs. Thus, the signaling pathways in regulating the
phenotypic determination are considered to be essentially
the same in visceral and vascular SMCs, and the SMC phe-
notype would be regulated by the balance between the
strengths of these signaling pathways. Although visceral
and vascular SMCs originate from different precursors,
our present findings provide a further insight in the com-
mon molecular mechanism of phenotypic determination
of two types of SMCs. This is because visceral and vascular
SMCs have common characteristics with respect to cell
structure, function, and expression of molecular markers
as follows. The main function of both types of SMCs is
contraction, which is Ca21-dependent and controlled by a
myosin-linked, actin-linked dual regulation (Sobue et al.,
1988, 1991). Both types of SMCs are rich in myofibrils and
are organized in a three-dimensional direction with two
prominent electron dense structures such as the dense
body in the cytoplasm and the dense membrane (dense
plaque) in cell–cell contact. Further, contractile and cy-
toskeletal proteins are also specifically expressed in and
serve as specific molecular markers for differentiated
SMCs. The expression patterns of these molecular mark-
ers are identical in both visceral and vascular SMCs and
their expression mechanisms, including transcription and
splicing, are also regulated in common ways (Owens 1995;
Sobue et al., 1998). Further studies are required to under-
stand the detailed signaling pathways in regulating the vas-
cular SMC phenotype and the functional linkage between
such signaling pathways and SMC-specific gene regulation
machineries, and to apply these findings to SMC disorders.
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